APA (7th ed.) Citation

Webster, L., Jansen, J. P., Peppin, J., Lasko, B., Irving, G., Morlion, B., . . . Carter, E. (2008). Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain (Amsterdam), 137(2), 428-440. https://doi.org/10.1016/j.pain.2007.11.008

Chicago Style (17th ed.) Citation

Webster, Lynn, et al. "Alvimopan, a Peripherally Acting Mu-opioid Receptor (PAM-OR) Antagonist for the Treatment of Opioid-induced Bowel Dysfunction: Results from a Randomized, Double-blind, Placebo-controlled, Dose-finding Study in Subjects Taking Opioids for Chronic Non-cancer Pain." Pain (Amsterdam) 137, no. 2 (2008): 428-440. https://doi.org/10.1016/j.pain.2007.11.008.

MLA (9th ed.) Citation

Webster, Lynn, et al. "Alvimopan, a Peripherally Acting Mu-opioid Receptor (PAM-OR) Antagonist for the Treatment of Opioid-induced Bowel Dysfunction: Results from a Randomized, Double-blind, Placebo-controlled, Dose-finding Study in Subjects Taking Opioids for Chronic Non-cancer Pain." Pain (Amsterdam), vol. 137, no. 2, 2008, pp. 428-440, https://doi.org/10.1016/j.pain.2007.11.008.